Obesity in Cardiorenal syndrome: Management Opportunities and Challenges
Current Hypertension Reports · 2025
DOI: 10.1007/s11906-025-01352-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Hypertension Reports, 2025. Verfasst von Allison Reaves und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Tufts Medical Center, 800 Washington Street, Box 391, Boston, MA, 02111, USA. Hauptthemen laut MEDLINE: Cardio-Renal Syndrome, Obesity. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
PURPOSE OF REVIEW: The prevalence of obesity continues to increase globally. There is accumulating evidence of the complex interplay between obesity, cardiovascular disease, particularly heart failure with preserved ejection fraction, and chronic kidney disease (CKD). Here, we review the diagnostic and management considerations for these co-existent conditions and the current evidence regarding the impact of obesity treatments on long term health outcomes. RECENT FINDINGS: Recent evidence suggests the pathophysiology of obesity, heart failure with preserved ejection fraction and CKD are inextricably linked as adipocytes appear to play a role in promoting renal sodium avidity and volume overload, which are the hallmarks of the cardiorenal syndrome. The clinical landscape of obesity management has changed significantly with the approval of glucagon-like peptide-1 receptor agonists, which have been shown to have cardiovascular and kidney benefit among patients with obesity and a range of comorbid conditions including diabetes, CKD, and heart failure. Improved recognition, diagnosis and management of clinically consequential obesity is emerging as a key factor in improving outcomes for patients with comorbid conditions such as heart failure with preserved ejection fraction and CKD. The incorporation of comprehensive multi-disciplinary management, shared decision making with patients and broader access to therapies is critical to improving clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Tufts Medical Center, 800 Washington Street, Box 391, Boston, MA, 02111, USA.
- Division of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
- Division of Nephrology, Tufts Medical Center, 800 Washington Street, Box 391, Boston, MA, 02111, USA. wmccallum@tuftsmedicalcenter.org.
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Reaves, A., Jaffe, E., & McCallum, W. (2025). Obesity in Cardiorenal syndrome: Management Opportunities and Challenges. Current Hypertension Reports. https://doi.org/10.1007/s11906-025-01352-5
Vancouver
Reaves A, Jaffe E, McCallum W. Obesity in Cardiorenal syndrome: Management Opportunities and Challenges. Current Hypertension Reports. 2025. doi:10.1007/s11906-025-01352-5
BibTeX
@article{Reaves2025,
author = {Reaves, Allison and Jaffe, Emily and McCallum, Wendy},
title = {Obesity in Cardiorenal syndrome: Management Opportunities and Challenges},
journal = {Current Hypertension Reports},
year = {2025},
doi = {10.1007/s11906-025-01352-5}
}
EUVIMED